Darshan Orna Ltd, AMD Industries Ltd, Sicagen India Ltd and B.C. Power Controls Ltd are among the other losers in the BSE's 'B' group today, 23 February 2021.

Vivimed Labs Ltd lost 19.94% to Rs 14.25 at 14:34 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 14.85 lakh shares were traded on the counter so far as against the average daily volumes of 54757 shares in the past one month.

Darshan Orna Ltd crashed 10.00% to Rs 13.05. The stock was the second biggest loser in 'B' group.On the BSE, 402 shares were traded on the counter so far as against the average daily volumes of 18652 shares in the past one month.

AMD Industries Ltd tumbled 8.57% to Rs 20.8. The stock was the third biggest loser in 'B' group.On the BSE, 56196 shares were traded on the counter so far as against the average daily volumes of 12076 shares in the past one month.

Sicagen India Ltd corrected 7.89% to Rs 14. The stock was the fourth biggest loser in 'B' group.On the BSE, 14516 shares were traded on the counter so far as against the average daily volumes of 9981 shares in the past one month.

B.C. Power Controls Ltd shed 6.30% to Rs 4.46. The stock was the fifth biggest loser in 'B' group.On the BSE, 6.07 lakh shares were traded on the counter so far as against the average daily volumes of 47989 shares in the past one month.

Powered by Capital Market - Live News

Vivimed Labs has received approval for 1 product from Uzbekistan Government for its PICS & Health Canada approved site, both facilities aresituated at Hyderabad.

PRODUCT: Paracetamol 125mg/5ml + Chlorpheniramine Maleate 2.5mg/5ml syrup under brandname FEBRIL Syrup 100ml

USES: Paracetamol is also known as acetaminophen, is a medication used to treat pain and fever.Chlorpheniramine is an antihistamine used to relieve symptoms of allergy, hay fever, and thecommon cold.

Powered by Capital Market - Live News

The drug company received approval for paracetamol 125mg/5mL + Chlorpheniramine Maleate 2.5mg/5ml syrup under brand name Febril syrup 100ml. Paracetamol is a medication used to treat pain and fever. Chlorpheniramine is an antihistamine used to relieve symptoms of allergy, hay fever, and the common cold.

Commenting on the approval, Ramesh Krishnamurthy, CEO of Vivimed Labs said, We are very excited to receive approval to Vivimed's own product FEBRIL Syrup 100ml. Vivimed strategy is to increase its share of branded products in CIS Markets. Vivimed shall be launching this product in 2021. Our purpose is to offer innovative & top-quality formulations at affordable prices. This approval is testimony to Vivimed's growth strategy.

Vivimed Labs is a pharmaceutical and chemical products company. The company's segments include speciality chemicals and pharmaceuticals.

On a consolidated basis, the company posted a net loss of Rs 49.55 crore in Q3 FY21 as against a net loss of Rs 32.07 crore in Q3 FY20. Net sales jumped 40.6% year on year to Rs 277.94 crore in Q3 FY21.

Powered by Capital Market - Live News

Net Loss of Vivimed Labs reported to Rs 49.55 crore in the quarter ended December 2020 as against net loss of Rs 32.07 crore during the previous quarter ended December 2019. Sales rose 40.59% to Rs 277.94 crore in the quarter ended December 2020 as against Rs 197.70 crore during the previous quarter ended December 2019.

Powered by Capital Market - Live News